Tomas Żarnowski, Maria Tulidowicz-Bielak. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Administration, TopicalAgedAngiogenesis Inhibitors/administration & dosageAntibodies, Monoclonal, Humanized/administration & dosageBevacizumabBlister/drug therapyConjunctiva/blood supplyHumansIntraocular PressureLow Tension Glaucoma/drug therapyLow Tension Glaucoma/surgeryMaleNeovascularization, Pathologic/drug therapyTrabeculectomyTreatment OutcomeVascular Endothelial Growth Factor A/antagonists & inhibitors
Substances: See more » Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedVEGFA protein, humanVascular Endothelial Growth Factor ABevacizumab
Year: 2009 PMID: 19925517 DOI: 10.1111/j.1755-3768.2009.01795.x
Source DB: PubMed Journal: Acta Ophthalmol ISSN: 1755-375X Impact factor: 3.761